Zurück zu Projekte

13385.1;4 PFFLR-LS

A novel antibody based therapy for allergy

Zusammenfassung

A novel antibody based therapy for allergy

Weitere Texte

Abstract

We intend to develop bispecific antibodies that target specifically IgE bearing B cells. Such bispecific antibodies will be evaluated for their capacity to inhibit IgE synthesis as well as to knock out IgE bearing B cells. The development of such antibodies represent an innovative approach as current therapeutic IgE-specific antibodies do not affect IgE production and therefore must be given frequently to maintain sufficient suppression of serum IgE. Glenmark has developed the necessary expression systems for bispecific antibodies and has all license agreement to market such antibodies. The academic partner has the individual anti-IgE antibodies that will be used for the construction of bispecific antibodies and will perform the preclinical testing in order to decide which construct will be taken up in the production pipeline.

Beteiligte

Monique Vogel

Kontaktperson

monique.vogel@iib.unibe.ch

Inselspital Bern Monique Vogel Sahlihaus 2 3010 Bern BE CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2012-03-31
Enddatum
2015-12-20
Bewilligte Gesamtkosten
CHF 338216.00
Sektion
5 KTI
NABS Politikbereich
Nicht aufteilbare / nicht zuteilbare Forschung

Forschungsdisziplinen

  • T115 Medical technology 100.0%